Fluconazole susceptibility of Candida species in Singapore by disc diffusion test

Annals of the Academy of Medicine Singapore

Volumn 31, Issue 4, 2002, Pages 497-501

  Oon, Lynette L E ^a   Yeo, M G C ^b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b NONE

Author keywords

Antifungal susceptibility testing; Disc diffusion method; Resistance

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; CLINICAL LABORATORY; DRUG SENSITIVITY; HUMAN; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; SPECIES DIFFERENCE; THRUSH;

EID: 0036654043     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Pfaller M A, Jones R N, Messer S A, Edmond M B, Wenzel R P. National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 1998; 31:327-32.
2. Rex J H, Rinaldi M G, Pfaller M A. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39:1-8.
3. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24:1122-8.
4. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Susceptibility Testing of Yeast. Approved Standard M27-A. Villanova, PA: National Committee for Clinical Laboratory Standards, 1997.
5. Barry A, Brown S. Fluconazole disk diffusion procedure for determining susceptibility of Candida species. J Clin Microbiol 1996; 34:2154-7.
6. Bille J, Glauser M P, and the Fluconazole Global Susceptibility Study Group. Evaluation of the susceptibility of pathogenic Candida species to fluconazole. Eur J Clin Microbiol Infect Dis 1997; 16:924-8.
7. Meis J, Petrou M, Bille J, Ellis D, Gibbs D, and the Global Antifungal Surveillance Group. A global evaluation of the susceptibility of Candida species to fluconazole by disc diffusion. Diagn Microbiol Infect Dis 2000; 36:215-23.
8. Sandven P. Detection of fluconazole-resistant Candida strains by a disc diffusion screening test. J Clin Microbiol 1999; 37:3856-9.
9. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing, Ninth Supplement to the M2-A6, M100-S9. Villanova, PA: National Committee for Clinical Laboratory Standards, 1999.
10. R Microbiology System, Santa Barbara, CA, 1999.
11. Rex J H, Pfaller M A, Galgiani J N, Bartlett M S, Espinel-Ingroff A, Ghannoum M A, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997; 24:235-47.
12. Pfaller M A, Jones R N, Doern G V, Sader H S, Hollis R J, Messer S A, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. J Clin Microbiol 1998; 36:1886-9.
13. Pfaller M A. Nosocomial candidiasis: Emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996; 22(Suppl 2):S89-94.
14. Iwen P C, Kelly D M, Reed E C, Hinrichs S H. Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole. Clin Infect Dis 1995; 20:342-7.
15. Goldman M, Pottage J C, Weaver D C. Candida krusei fungemia: report of 4 cases and review of the literature. Medicine (Baltimore) 1993; 72:143-50.
16. Ghannourn M A. Is antifungal susceptibility testing useful in guiding fluconazole therapy? Clin Infect Dis 1996; 22(Suppl 2):S161-5.